- THRIVE Grant
Amount: $50,000 over 2 years
Deadline: LOI due April 8, 2024
Eligibility:
Principal investigator(s) must hold an M.D., Ph.D., D.V.M., or equivalent degree.
Awardees must be willing to participate in the annual HESI THRIVE research forum – an opportunity to share results and build a network of experts.
About: Supports investigators for the testing of initial hypotheses and collecting of preliminary data to help secure long-term funding by the National Institutes of Health and/or other major granting institutions. - Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Consortium Request for Project Proposals (RPP) RRPV-24-03-Treatment Next Generation Therapeutics for COVID-19
Deadline: April 8, 2024 at 1 PM
This RPP is requesting project proposals from product developers for the advanced clinical development and assessment of Next-Generation Therapeutics for COVID-19. The purpose of this project is to partner with developers and other organizations to advance the clinical development of Next-Generation Therapeutics for COVID-19, specifically treatment. The goal of this project is to provide better COVID-19 solutions and bolster preparedness and response against future health security threats. - Orthopaedic Research & Education Foundation: OREF/Goldberg Arthritis Research Grant
Amount: $50,000
Deadline:
LOI: N/A
Application: April 11, 2024
Eligibility:
The PI must be a new investigator. A new investigator is classified as an individual who has not received an R01 National Institutes of Health grant or its equivalent in the role of PI.
An orthopaedic surgeon PI must be licensed to practice in the U. S. and be working in an institution in the U.S. A PhD may serve as the PI and must hold a faculty appointment in an orthopaedic department at an institution in the U.S. A letter from the department chair confirming the appointment is required.
A DVM may serve as the PI but must have a primary appointment in an orthopaedic department. Listing an orthopaedic surgeon as the Co-PI is required. A letter from the department chair confirming the appointment is required.
About: Provides seed and start-up funding for promising research projects that address issues related to the treatment of arthritis with an emphasis on arthroplasty. - Orthopaedic Research & Education Foundation: OREF/ASES Rockwood Clinical Shoulder Research Grant
Amount: $50,000
Deadline:
LOI: N/A
Application: April 11, 2024
Eligibility:
Either the PI or co-PI must be a member of the American Shoulder and Elbow Surgeons.
The PI must be a new investigator. A new investigator is classified as an individual who has not received an R01 National Institutes of Health (NIH) grant or its equivalent (e.g., VA, DOD, NSF) in the role of PI. An orthopaedic surgeon PI must be licensed to practice in the U. S. and be working in an institution in the U.S. A PhD may serve as the PI and must hold a faculty appointment in an orthopaedic department at an institution in the U.S. A letter from the department chair confirming the appointment is required.
About: Provides funding for new investigators to conducting research in the area of shoulder care. - Whitehall Foundation: Research Grants
Amount: Up to $300,000 over 3 years
Deadline: LOI due April 15, 2024
Eligibility:
Appropriate title – must be an Assistant Professor (or higher). If the institution does not use this title, a letter from the department chair confirming the applicant’s eligibility is required.
Status – must hold Principal Investigator status.
Independent – must be considered an ‘independent investigator’ with their own dedicated lab space or with lab space independent of another investigator.
The Foundation does not fund investigators who have substantial (approximately $200,000 per year) extramural funding. The Foundation uses the following formula to determine the PIs total extramural funding: Total direct per year plus total indirect per year less any PI salary taken from these grants. If this amount is greater than approximately $200,000 the PI would not be eligible for Whitehall Foundation funding. Startup funds and internal funding are not included in the calculation.
About: Supports scholarly research in the life sciences. It is the Foundation’s policy to assist those dynamic areas of basic biological research that are not heavily supported by Federal Agencies or other foundations with specialized missions. The Foundation is currently interested in basic research in neurobiology, defined as follows: Invertebrate and vertebrate (excluding clinical) neurobiology, specifically investigations of neural mechanisms involved in sensory, motor, and other complex functions of the whole organism as these relate to behavior. The overall goal should be to better understand behavioral output or brain mechanisms of behavior. - Whitehall Foundation: Grants in Aid
Amount: $30,000 over 1 year
Deadline: LOI due April 15, 2024
Eligibility:
Appropriate title – must be an Assistant Professor (or higher). If the institution does not use this title, a letter from the department chair confirming the applicant’s eligibility is required.
Status – must hold Principal Investigator status.
Independent – must be considered an ‘independent investigator’ with their own dedicated lab space or with lab space independent of another investigator.
The Foundation does not fund investigators who have substantial (approximately $200,000 per year) extramural funding. The Foundation uses the following formula to determine the PIs total extramural funding: Total direct per year plus total indirect per year less any PI salary taken from these grants. If this amount is greater than approximately $200,000 the PI would not be eligible for Whitehall Foundation funding. Startup funds and internal funding are not included in the calculation.
About: Supports researchers at the assistant professor level conducting scholarly research in the life sciences who experience difficulty in competing for research funds because they have not yet become firmly established. Grants-in-Aid can also be made to senior scientists. It is the Foundation’s policy to assist those dynamic areas of basic biological research that are not heavily supported by Federal Agencies or other foundations with specialized missions. The Foundation is currently interested in basic research in neurobiology, defined as follows: Invertebrate and vertebrate (excluding clinical) neurobiology, specifically investigations of neural mechanisms involved in sensory, motor, and other complex functions of the whole organism as these relate to behavior. The overall goal should be to better understand behavioral output or brain mechanisms of behavior. - Cystic Fibrosis Foundation Funding Opportunities
LOI Deadline: April 23, 2024
The 2024 Health Equity Team Science Award (HETSA) with LOI is offered to provide support for multi-investigator research projects that have the potential to improve our understanding of or have a positive impact on identified barriers to optimal health outcomes for all people with CF related to race and ethnicity, sexual orientation or gender, or socioeconomic status. It is required that each study team include at least one member with a strong track record of publishing in the health equity research field demonstrating established expertise in health equity research.
For questions, please contact Dara Riva (driva@cff.org). - The Nathan Cummings Foundation Open Call for Funding Proposals
Application Due: April 30, 2024
Venture Grants: (up to $100K) These grants are short-term and designed to provide expedited support to social entrepreneurs with breakthrough and innovative solutions.
Advancement Grants: (up to $250K) These grants are designed to provide two-year support to project-based work and/or help scale organizations and promising solutions.
Enterprise Grants: ($250k+) These grants are designed to provide multi-year, unrestricted funding to partners that have deep alignment across our REEJ focus areas and offer the most opportunity to use all our financial and non-financial resources to support their solutions. - International Center for Responsible Gaming: Grants Available for Research on Prevention/Responsible Gambling
Deadline: June 3, 2024
The International Center for Responsible Gaming (ICRG) invites investigators to apply for a three-year grant to study the impact of safer gambling messaging including its impact on gambling behavior and use of responsible gambling tools. The ICRG will award one grant in this competition. Applicants may request up to $402,500 for a three-year grant. - Cystic Fibrosis Foundation: Therapeutics Development Award Component II – Clinical Phase
Amount: Up to $5 million over 3 years
Deadline: LOIs reviewed on a rolling basis
Eligibility:
Awards will be made for preclinical and initial clinical development activities (all therapeutic areas relevant to CF).
In special circumstances CFF support may be used for API manufacture or other chemistry, manufacturing and controls activities, clinical trials involving healthy human subjects, support of senior company personnel engaged in administrative roles or Phase III multi-center clinical trials. However, these activities are generally viewed as the responsibility of the sponsor and may be recognized as matching funds.
All projects should be conducted in consultation with a CF-identified investigator representing a CFFaccredited Center, CF-supported Therapeutic Development Center, other funded mechanism by the CFF, or other funding agencies, and subject to approval by CFF.
Approved awards will be subject to monitoring by a Project Advisory Group (PAG), whose membership is approved by CFF. If applicable, the PAG will determine overall performance of the project. If applicable, the PAG will report to CFF on a periodic basis not less than once every three (3) months. Continued support may also depend on the PAG’s approval of project milestones.
Milestones: Each application must contain milestones that are objective achievements demonstrating forward progress for the therapeutic approach and the appropriate timetable for completion of each. Continued funding for the project will be, in part, based upon milestone attainment.
About: The objective of this phase is to provide support for the continuation of preclinical studies and clinical assessment of new interventions, including safety and dose determination studies in CF patients. In special circumstances funding may be provided for chemistry manufacturing and controls (CMC) related activities or studies in healthy human subjects. - Research to Prevent Blindness: RPB Challenge Grant
Amount: $300,000
Deadline: July 1, 2024 Fall Cycle
Eligibility:
An existing base of high-quality National Eye Institute (NEI) or vision-related research grants is a primary requirement.
The department must be in an upward trajectory and strong faculty/professional development programs must be in place.
A commitment by the medical school to match the RPB Challenge Grant is required.
Department chairs receiving an Unrestricted Grant and individual members of their faculties are not eligible to apply for this grant.
About: RPB Challenge Grants encourage growth for newly emerging eye research programs and recently appointed department chairs at non-grantee ophthalmology departments at university-connected medical schools. The Challenge Grant is designed to enhance a department’s environment and capability to conduct vision research, to facilitate collaborative studies of the visual system, and to attract researchers to the department. The Challenge Grant is intended for ophthalmology departments which have not received RPB departmental support (Unrestricted or Challenge) in the last four (4) years.
Apply:
The application forms for this award are not available online. Contact Pattie Moran (pmoran@rpbusa.org) to obtain the Unrestricted Grant application forms. - Research to Prevent Blindness – Unrestricted Grant
Amount: $115,000
Deadline: July 1, 2024 Fall Cycle
Eligibility:
Only departments of ophthalmology with a full-time, permanent chair at university-connected medical schools are eligible for support.
It is suggested that new chairs be active for at least six months before applying.
If a proposal for an Unrestricted Grant is rejected, the chair must wait two years before reapplying.
About: RPB Unrestricted Grants provide maximum flexibility in developing and expanding eye research programs. These grants provide opportunities for creative planning that go beyond the scope of restricted project grants which scientists normally depend upon for their principal support.
Funds automatically renew for five years unless the ophthalmology chair steps down or RPB requires the department to re-apply earlier. Advance notice will be given if the grant is to be terminated. Should the chair step down, RPB may provide one additional payment before the grant is terminated. An acting or interim chair cannot re-apply for continued support.
Payments can continue for up to four years upon approval of a two-year substantive progress report. After four years, chairs will then be invited to apply for an Unrestricted Grant.
Apply:
The application forms for this award are not available online. Contact Pattie Moran (pmoran@rpbusa.org) to obtain the Unrestricted Grant application forms. - Cystic Fibrosis Foundation: Therapeutics Development Award Component I –Preclinical Development Phase
Amount: $600,000 over 3 years
Deadline: LOIs reviewed on a rolling basis
Eligibility:
Awards will be made for preclinical and initial clinical development activities (all therapeutic areas relevant to CF).
In special circumstances CFF support may be used for API manufacture or other chemistry, manufacturing and controls activities, clinical trials involving healthy human subjects, support of senior company personnel engaged in administrative roles or Phase III multi-center clinical trials. However, these activities are generally viewed as the responsibility of the sponsor and may be recognized as matching funds.
All projects should be conducted in consultation with a CF-identified investigator representing a CFFaccredited Center, CF-supported Therapeutic Development Center, other funded mechanism by the CFF, or other funding agencies, and subject to approval by CFF.
Approved awards will be subject to monitoring by a Project Advisory Group (PAG), whose membership is approved by CFF. If applicable, the PAG will determine overall performance of the project. If applicable, the PAG will report to CFF on a periodic basis not less than once every three (3) months. Continued support may also depend on the PAG’s approval of project milestones.
Milestones: Each application must contain milestones that are objective achievements demonstrating forward progress for the therapeutic approach and the appropriate timetable for completion of each. Continued funding for the project will be, in part, based upon milestone attainment.
About: The objective of this phase is to establish the technical merit and feasibility of a new therapeutic intervention. Qualifying activities may include medicinal chemistry efforts to improve drug-like properties and preliminary compound testing for pharmacokinetics and bioavailability, as well as specificity and determination of mechanism of action. - Crohn’s & Colitis Foundation – IBD Plexus Academic Request for Proposals
Rolling Submission
The goal of IBD Plexus is to accelerate research in high impact areas. The Foundation seeks research proposals that would utilize IBD Plexus biosamples and / or data to drive progress towards precision medicine and / or leverage real world data to produce real world evidence. - NSF-BSF Program in Computer Networks and Systems
Rolling Submission
The U.S.-Israel Binational Science Foundation (BSF) is accepting applications in a joint funding program with the Division of Computer and Network Systems (CNS), in the Directorate for Computer and Information Science and Engineering (CISE) of the U.S. National Science Foundation (NSF). - NSF-BSF PROGRAM IN Foundational Research in Robotics
Rolling Submission
The U.S. – Israel Binational Science Foundation (BSF) is accepting applications in joint funding programs in Foundational Research in Robotics, with the Computer and Information Science and Engineering (CISE); Engineering (ENG) Directorates of the U.S. National Science Foundation (NSF). - Tourettes Association: Research Consortia and Collaborative Research Projects
Rolling Submission
TAA has historically provided critical seed funding to research consortia working on large issues relevant to TS, including the TAA genetics consortium, neuroimaging consortium, behavioral sciences consortium, deep brain stimulation registry and Treating Tourette Together summit. TAA aims to continue supporting research efforts like these, that crossover different scientific and medical disciplines and that encourage collaboration among researchers and institutions.
Development Office’s Corporate and Foundation (C&F)
The Development Office’s Corporate and Foundation (C&F) Team identified the below funding opportunities. To apply, please contact DevCorpFound@mountsinai.org. The C&F team will help plan, write, and submit your application.
- Prostate Cancer Foundation: 2024 PCF Challenge Awards for Metastatic, Lethal Prostate Cancer
Deadline:
LOI: April 8, 2024
Full Application: June 17, 2024
Amount: $1,000,000 per team over two years
About: PCF announced a Request for Team Science Applications for PCF Challenge. Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world.
Encourage applications on prostate cancer disparity research that will help to define the origins of differential outcomes for prostate cancer patients in men of under-represented populations, including those focusing on biology or health care access policy. The foundation also seeks applications conducting research in VA hospitals where research directly affects veterans with advanced.
Research proposals in the following topics are preferred:
Immunotherapy for the treatment of metastatic, lethal prostate cancer.
Targeted radionuclide therapy for advanced prostate cancer.
New systemic precision treatments for metastatic, lethal prostate cancer including those targeting the currently ‘undruggable’.
First-in-field research on new targets for systemic treatment of metastatic, lethal prostate cancer.
Mechanisms of resistance to current and investigational drugs targeting the androgen receptor and androgen axis, immune system, chemotherapy, and other targeted agents.
Correlative research around either clinical trials of novel agents or strategies or standard of care.
Determinants of survivorship that will improve the lives of patients with metastatic prostate cancer.
Developing or validating biomarkers that guide therapy in patients or further our understanding of the mechanisms by which therapies work.
Tumor microenvironment signaling related to cancer progression including the immune component.
New data science technologies for analysis of genomic information to advance precision medicine.
Research to define causes and solutions for racial and ethnic prostate cancer health disparities
Eligibility:
Composed of a team of at least three investigators from non-profit academic research centers, including one young investigator.
Cover only direct research costs and travel to the Annual PCF Scientific Retreat.
Clinical trial direct costs are not allowed; however, correlative research to support high impact clinical trials for advanced prostate cancer is encouraged. IRB submission and preferably approval is desired at the time of application.
All studies involving patients must include plans for including diverse participant populations with appropriate representation of ethnic and racial minority groups. Comprehensive statistical plans and power calculations are required. - Pfizer Independent Medical Education RFP Addressing Knowledge Gaps in Ulcerative Colitis (UC) Care
Amount: Up to $200,000
Deadline: April 8, 2024
Eligibility: —
About: The purpose of this RFP is to enhance education for healthcare professionals (HCPs), specifically community Gastroenterologists and Advanced Practice Providers (APPs), involved in diagnosis, treatment, and management of patients with UC. Particularly interested in programs that focus on educational needs in UC, including but not limited to:
Education of new oral therapies for UC including S1P modulators mechanism of action and data
Education on transition from conventional to advance therapy in UC (treat to target and shared decision making)
Burden of disease and management of isolated proctitis in UC - Pfizer Fellowship Grant RFP 2024 Inflammatory Bowel Disease (IBD) Fellowship – United States
Amount: $80,000 over 1 year
Deadline: April 15, 2024
Eligibility:
Do not include the name of the potential fellow(s) in application materials. This grant will be awarded to an institution, not an individual.
Institutions with fellowship programs that include independent research and a strong mentoring program. Clinical training may be included in the program but is not required.
Examples of independent research include: observational studies and outcomes research studies where the primary focus is the scientific understanding of disease; use of screening tools and their impact on improvement of patient health.
Examples of research that would not be eligible include research involving the study and/or evaluation of any pharmaceutical product and basic science and/or fundamental research (in animal model, in-vitro, etc.).
Examples of clinical training include: educational time with an interdisciplinary team in review of case examples and relevant didactic training as well as use of tools for improvement in patient health for specific therapeutic areas or conditions.
Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care
About: The goal of this RFP is to offer salary support for IBD fellowship programs. It is our intent to support fellowship programs at institutions with clinical training programs in regions where there are continued workforce challenges and that have a strong focus on clinical practice, research, and education to further the understanding of IBD.
Preference will be given to programs that are located in states underserved by number of GI fellowships and serving an underserved population. Grants will be awarded based on the strength of the requesting organization’s ability to provide expert mentorship, training, and guidance to the fellow - RTW Charitable Foundation: Community Grant
Amount: Up to $50,000
Deadline: LOI due April 15, 2024
Eligibility:
This opportunity is open exclusively to 501(c)(3) non-profit organizations in New York City.
About: Supports projects that that seek to address the gaps in care for communities of color, low-income families, recent immigrants, and other underserved populations. Initiatives can include (but are not limited to) community-based health services, innovative ways to connect community members with no-/low-cost care options and health insurance, initiatives to improve health equity measures within health systems, and action-oriented health equity research. - 2024 Genentech Health Equity Innovation Fund
Amount: Up to $750,000 over 3 years
Deadline: LOI due April 15, 2024
Eligibility:
Specifically seeking proposals that address inequities in patient outcomes and healthcare workforce experiences across at least one of the therapeutic areas below:
Neuroscience and Brain Health, including but not limited to multiple sclerosis
Oncology, including but not limited to Breast, Lung, & hepatocellular carcinoma (HCC)
Ophthalmology, including but not limited to diabetic macular edema
Cardiovascular and Metabolic Disease, including but not limited to diabetes,
In order to be eligible for this type of funding, the funding must not be used for:
The purpose of developing clinical practice guidelines (e.g., statements that include recommendations intended to help practitioners make appropriate health care decisions for specific clinical conditions)
About: Supports proposals that are designed to measurably and sustainably close racial and ethnic inequities in healthcare. Priority will be given to proposals that bring a systemic lens: cutting across multiple outcomes with a focus on root causes to realize the long-term future indicated above. The goal of this funding is to achieve a long-term future where:
All patients—especially those marginalized by our healthcare system—define and attain their highest levels of health supported by a system that is accountable for delivering access to high-quality competent care
The medical and scientific workforce is diverse, inclusive, thriving, and accountable to the needs of all patients - AACR CANCER DISPARITIES RESEARCH FELLOWSHIPS
Amount:$130,000 over 2 years
Deadline: April 16, 2024
Eligibility:
Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree.
At the start of the grant term on August 1, 2024, applicants must:
Hold a mentored research position with the title of postdoctoral fellow, clinical research fellow, or the equivalent
If eligibility is based on a future position, the position must be confirmed at the time of application and CANNOT be contingent upon receiving this grant.
If the future position is at a different institution than the applicant’s current institution, the applicant must contact the AACR’s Research and Grants Administration Department (AACR’s RGA) at grants@aacr.org before submitting their application for information on additional verification materials/signatures that may be required.
Have completed their most recent doctoral degree within the past five years (i.e., degree cannot have been conferred before August 1, 2019; the formal date of receipt of doctoral degree is the date the degree was conferred, as indicated on their diploma and/or transcript).
Applicants with a medical degree must have completed their most recent doctoral degree or medical residency – whichever date is later – within the past five years.
Work under the auspices of a mentor at an academic, medical, or research institution anywhere in the world.
About: Supports postdoctoral or clinical research fellows to conduct cancer disparities research and to establish a successful career path in this field. The proposed research may be in basic, translational, clinical, or population sciences research and must have direct applicability and relevance to cancer disparities. - Lupus Research Alliance: Translational Bridge Award
Amount: $450,000 over 2 years
Deadline: LOI due April 29, 2024
Eligibility:
Applicants must have previously received LRA funding or were affiliated with a previously funded LRA award and have completed or will complete the award term, inclusive of any no-cost extensions, between January 1, 2019, and December 31, 2024. Current LRA funded investigators whose awards will be completed after December 31, 2024, are not eligible to apply.
Applicants must have a doctoral degree (MD, PhD, DO, or equivalent), holding a faculty, or equivalent, position and leading an independent research team at an academic, nonprofit, or government research institution.
Applicants must also be up to date with all progress and financial reports and other Terms and Conditions of the original LRA award(s) at the time of application.
The same research project may not be submitted for consideration to multiple LRA grant mechanisms in the same year. Such submissions will be triaged without review.
About: Provides funding to bridge the gap between post-discovery and pre-commercial development and to accelerate the pace at which promising LRA-funded foundational research discoveries are translated into clinical evaluation and transitioned to a viable product that impacts patients directly. All projects should advance potential commercial entities or clinical products with a clear and direct relevance to people with lupus and offer the potential to improve diagnosis or standard of care for the disease or usher in a cure. These can include a range of technologies, therapies, interventions, and diagnostics. - IARS Mentored Research Awards (IMRA)
Amount: $175,000 over 2 years
Deadline: April 30, 2024
Eligibility:
Principal applicant must be an IARS member.
Principal applicant must be an investigator who has yet to establish substantial independent research funding or who is initiating a new area of research.
Duration since completion of clinical training or PhD must be under 10 years.
Applicants must have a minimum of 45% protected non-clinical time.
Prior or current recipients of NIH R grants, NIH K grants, AHA Young Investigator Awards, VA Career Development Awards, or the equivalent, are not eligible to apply. IMRA recipients may not be simultaneously receiving support from an NIH T32 grant. IARS does not allow for concurrent funding of an IMRA with these or similar awards.
Prior or current recipients of Foundation for Anesthesia Education and Research (FAER) Mentored Research Training grants are not eligible to apply.
Prior or current recipients of award dollars totaling more than $90,000/year are not eligible
About: Supports investigations that will further the understanding of clinical practice in anesthesiology and related sciences. - CareQuest – Veteran Oral Health: Expanding Access and Equity
Amount: $125,000
Deadline: May 1, 2024
Eligibility: —
About: Supports projects and partner with organizations that are working to address system-level barriers to oral health for veterans. - Lennox-Gastaut Syndrome Foundation: Cure LGS 365 Research Grants
Deadline: LOIs due May 1, 2024, with rolling decisions
Amount: $25,000-75,000
About: Projects may be on any novel topic in LGS but must be directly relevant to LGS, which is characterized by specific seizure types and hallmark EEG features. - ASH Bridge Grant
Amount: $150,000 over 1 year
Deadline: May 1, 2024 (Application opens March 1, 2024)
Eligibility:
To be considered for an ASH Bridge Grant, the applicant must:
Have submitted to the NIH in the past 18 months a hematology-related R01 or R01-equivalent application that was scored but not funded. This includes investigators applying for their first R01.
Please note: The 18-month timeframe begins the date your R01 was reviewed by the NIH study section.
Be an ASH member in good standing and plan to maintain membership for the duration of the award term.
Hold a faculty position at an academic institution or the equivalent position at a non-profit research organization. Employees of independent research institutions are eligible to apply if they have a faculty-type appointment and the institution is allowed to independently apply for and receive NIH funding.
Have the commitment of his/her institution to match $50,000 in funds.
At the time of award activation, have available no more than $250,000 annually in other research funding. This amount does not include the applicant’s salary/fringe or funding from within the institution.
Exclusions:
Previous Bridge Grant recipients cannot apply for a second award.
Individuals cannot apply for the Bridge Grant more than three times.
Requests for exceptions can be made when grants have been completely written with new aims and new questions asked.
Individuals eligible to apply for the ASH Scholar Award are not eligible to apply for the ASH Bridge Grant.
Individuals cannot hold two active ASH awards concurrently. If the other ASH award ends before the Bridge Grant begins, you may apply but there can be no overlap.
About: Supports ASH members who applied for an NIH R01 grant or equivalent and were scored but not funded. ASH Bridge Grants are intended to help sustain recipients’ research and contribute to their retention in hematology investigation while they reapply. - ASH Junior Faculty Scholar Award
Amount: $150,000 over 2-3 years
Deadline: LOI due May 1, 2024
Eligibility:
MD/DO, PhD or MD/DO-PhD applicants must have more than eight years (96 months) and 13 or fewer years (156 months) of research experience after completion of their terminal doctoral degree (including research performed during fellowship but excluding clinical fellowship time).
Applicants with more than 5 years (60 months) and eight or fewer years (96 months) of research experience who have already received, or do not meet the eligibility requirements for the Fellow to Faculty Scholar Award, are eligible to apply for the Junior Faculty Scholar Award.
Applicants who hold independent faculty level positions (Assistant Professor, or equivalent – which may be indicated by having achieved the appointment after an external search and/or if the individual has voting rights as a member of the faculty) must apply for the Junior Faculty Award, regardless of research experience. Individuals serving as an ‘acting’ faculty member may be excluded from this requirement.
About: Supports researchers during transition between training and the establishment of an independent career in hematology research by providing partial salary or other support during that critical period. Applicants must submit proposals to conduct research in hematology. Proposals that fall within any of the categories discussed below are encouraged:
Basic Research
Translational Research
Patient-Oriented Clinical Research
Outcomes-Based Research - ASH Fellow Scholar Award
Amount: $100,000 over 2-3 years
Deadline: LOI due May 1, 2024
Eligibility:
The Fellow Scholar Award is intended for individuals preparing for academic careers.
Applicants must be in mentored, postdoctoral training positions to be eligible to apply for a Scholar Award.
MD/DO applicants should have more than three years (36 months) and five or fewer years (60 months) of research experience after completion of their MD/DO (including research performed during fellowship but excluding clinical fellowship time).
MD/DO applicants with three or fewer years (36 months) of research experience (inclusive of fellowship research time) should consider applying for the senior investigator Research Training Award for Fellows.
PhD or MD/DO-PhD applicants must have five or fewer years (60 months) of research experience after completion of their terminal doctoral degree. (including research performed during fellowship but excluding clinical fellowship time).
Applicants who hold independent faculty level positions (Assistant Professor, or equivalent – which may be indicated by having achieved the appointment after an external search and/or if the individual has voting rights as a member of the faculty) must apply for the Junior Faculty Award, regardless of research experience. Individuals serving as an ‘acting’ faculty member may be excluded from this requirement.
About: Supports researchers during transition between training and the establishment of an independent career in hematology research by providing partial salary or other support during that critical period. Applicants must submit proposals to conduct research in hematology. Proposals that fall within any of the categories discussed below are encouraged:
Basic Research
Translational Research
Patient-Oriented Clinical Research
Outcomes-Based Research - PhRMA Foundation: Drug Delivery Postdoctoral Fellowship
Amount: $120,000 over 2 years
Deadline: LOI due May 1, 2024
Eligibility: .
Applicants must hold a PhD, PharmD, MD, or appropriate terminal research doctorate. If you do not hold one at the time of application submission, please state in your extended letter when you expect to receive it, as it must be received before funding can begin. Funding can begin as early as January 1, 2025, or as late as August 1, 2025.
Applicants must be within their first three years of postdoctoral study at the time of award activation. You are not eligible if you have started your fourth year of postdoctoral study by January 1, 2025.
Applicants who are applying for funds to support postdoctoral work in the laboratory where their graduate work was performed will be given lower preference. One of the objectives of this fellowship is to gain new skills, and therefore, an ideal candidate will be conducting their research in a new laboratory and not where their graduate work was performed.
The Foundation will not consider multiple applications for similar efforts on the same project. For instance, if a predoc, postdoc, and faculty member from the same lab are all submitting applications for proposed efforts on the same project, the efforts must be separate activities and not duplicative.
About: Supports individuals (U.S. and non-U.S. citizens) engaged in a multidisciplinary, collaborative research training program at an accredited U.S. university that will extend their credentials in drug delivery research, including basic pharmaceutics, biopharmaceutics, pharmaceutical technology, pharmaceutical biotechnology, or biomedical engineering. - PhRMA Foundation: Drug Delivery Faculty Starter Grant
Amount: $100,000 over 1 year
Deadline: LOI due May 1, 2024
Eligibility:
Applicants (U.S. and non-U.S. citizens) must be full-time, promotion-eligible, research-intensive faculty at a PhD and/or MS degree-granting accredited U.S. university.
Applicants must be within the first three years of independent status at the time of award activation. You are not eligible if you have started your fourth year of independent status by January 1, 2025.
Applicants must be eligible to apply for independent external research funding by their university.
Applicants should not have other substantial sources of research funding. (For example, applicants are ineligible if they are the principal investigator of an R01 from the National Institutes of Health, a career award from the National Science Foundation, or other similar award.) Individuals receiving only intramural funding or start-up funding from their university are eligible to apply.
The Foundation will not consider multiple applications for similar efforts on the same project. For instance, if a predoc, postdoc, and faculty member from the same lab are all submitting applications for proposed efforts on the same project, the efforts must be separate activities and not duplicative.
About: Supports individuals beginning independent careers at the faculty level at an accredited U.S. university in drug delivery research, including basic pharmaceutics, biopharmaceutics, pharmaceutical technology, pharmaceutical biotechnology, or biomedical engineering. Applicants must be within the first three years of their independent status. - PhRMA Foundation: Drug Delivery Predoctoral Fellowship
Amount: $60,000 over 2 years
Deadline: LOI due May 1, 2024
Eligibility:
Applicants (U.S. and non-U.S. citizens) must attend an accredited U.S. university as full-time, in-residence students.
Individuals just beginning graduate school should not apply. Applicants will have completed most of their pre-thesis requirements (at least two years of coursework) and be engaged in thesis research as PhD candidates by the time the award is activated. Award activation can begin as early as January 1, 2025, or as late as August 1, 2025.
Applicants should expect to complete their PhD requirements in two years or less from the time funding begins. The thesis advisor’s letter of support must verify the applicant’s doctoral candidacy.
Applicants who expect to complete their PhD before December 31, 2025, are not eligible.
Applicants enrolled in MD/PhD programs should not be engaged in required clinical coursework or clerkships while the fellowship is active. Fellows are expected to devote full time (including summers) to their research.
Predoctoral fellowships should not be seen as a way to fund the principal investigator’s currently funded research project.
The Foundation will not consider multiple applications for similar efforts on the same project. For instance, if a predoc, postdoc, and faculty member from the same lab are all submitting applications for proposed efforts on the same project, the efforts must be separate activities and not duplicative.
About: Provides support for promising students (U.S. and non-U.S. citizens) in advanced stages of training and thesis research in drug delivery research, including basic pharmaceutics, biopharmaceutics, pharmaceutical technology, pharmaceutical biotechnology, or biomedical engineering. - Male Contraceptive Initiative Development Awards
Amount: Up to $400,000 over 2 years
Deadline: LOI due May 13th, 2024
Eligibility:
Projects in active contraceptive development that have identified a lead compound or series, are in pursuit of or have achieved regulatory approval for first-in-human studies, or are otherwise well-positioned for downstream development are eligible for Development Awards.
Applications focusing on pharmacological modulation of defined molecular targets must provide Proof of Concept that the proposed modulation will block male fertility. Proof of Concept in an animal model is preferred.
Applicants may submit more than one application, provided that each application is scientifically distinct
MCI will not accept applications that are duplicate or highly overlapping grant awards from other funding agencies. Applications in the following areas are considered not responsive and will not be reviewed:
Approaches developing contraceptives that are delivered to female users only
Approaches that permanently inhibit fertility, e.g. cause sterility or other defects in reproduction after cessation of treatment
Male or female barrier development, e.g. condoms
Approaches involving the administration of steroid hormones to manipulate the hypothalamic–pituitary–gonadal axis (HPG axis)
Approaches that induce active immunity
Applications focused on molecular targets for which there is no human ortholog
About: The emphasis for this funding opportunity is encouraging the development of safe, effective, and reversible male contraceptives that are distinct from existing methods and have profiles that appeal to a broad base of users. Projects in early-to-late stages of contraceptive development, including preclinical studies and beyond.
Small Molecule Therapeutics
Chemical matter is at the lead optimization or preclinical stage. The target is known, and/or there is some method or assay to assess modulation of the target.
Biologics or Cell Based Therapies
The biologic has been identified and there are established in vivo efficacy and target engagement data.
Interventional Medical Device
Physiologic experiments have been conducted or reported in the literature, The device is in a stage of active development and the proposal includes activities such as manufacturing certification, ISO 10993 testing, design optimization, providing rationale for prototype development.
Tool, Assay, Delivery Device, Diagnostic, or Other Research Focus
Tools must be at an advanced stage of development and offer significant access and upside to the scientific community for Development Award consideration. Applicants seeking a Development Award for this approach should contact the appropriate MCI official at the earliest opportunity - Male Contraceptive Initiative David Sokal Innovation Awards
Amount: Up to $200,000 over 2 years
Deadline: LOI due May 13th, 2024
Eligibility:
Projects exploring contraceptive targets through identifying potential contraceptive compounds are eligible for David Sokal Innovation Awards
Applications focusing on pharmacological modulation of defined molecular targets must provide Proof of Concept that the proposed modulation will block male fertility. Proof of Concept in an animal model is preferred.
MCI will not accept applications that are duplicate or highly overlapping grant awards from other funding agencies. Applications in the following areas are considered not responsive and will not be reviewed:
Approaches developing contraceptives that are delivered to female users only
Approaches that permanently inhibit fertility, e.g. cause sterility or other defects in reproduction after cessation of treatment
Male or female barrier development, e.g. condoms
Approaches involving the administration of steroid hormones to manipulate the hypothalamic–pituitary–gonadal axis (HPG axis)
Approaches that induce active immunity
Applications focused on molecular targets for which there is no human ortholog
About: The emphasis for this funding opportunity is encouraging the development of safe, effective, and reversible male contraceptives that are distinct from existing methods and have profiles that appeal to a broad base of users. Projects in discovery or exploratory phases of contraceptive development, including hit-to-lead optimization.
Small Molecule Therapeutics
Proposals can include activities such as target / hit identification, hit-to-lead optimization, and in vitro / in vivo assessments as appropriate.
Biologics or Cell Based Therapies
Proposals should lead to new molecular entities and include some measure of assessment of efficacy in an in vitro / in vivo model.
Interventional Medical Device
The proposal includes prototype development and testing, either on the bench or in animals. Physiologic experiments have been conducted or reported in the literature,
Tool, Assay, Delivery Device, Diagnostic, or Other Research Focus
Proposals should be aimed at developing methods, techniques, assays, or devices that provide new or enhanced diagnostic, screening, or delivery capabilities. Practical application and dissemination of information should be included in the scope of work. - Freeman Hrabowski Scholars Program
Amount: $8.6M over 10 years
Deadline: May 15, 2024
Eligibility:
Hold a PhD and/or MD (or equivalent)
Began their first post-training position and began a tenure-track (or equivalent) faculty position on or after March 1, 2020, or have accepted an offer for a tenure-track (or equivalent) position that will begin no later than March 1, 2025
Maintain a tenure-track appointment or equivalent at an eligible US institution (Federal government employees are not eligible.)
Have a research focus in the biological and biomedical sciences, working across many scientific disciplines in a wide range of organisms
Are authorized to work in the US or can obtain work authorization for the duration of employment (HHMI sponsors visas for eligible individuals.)
About: Supports outstanding basic researchers, including physician-scientists, who have strong potential to become leaders in their fields and to advance diversity, equity, and inclusion through their mentoring efforts and understanding of systemic exclusion and marginalization in science of trainees from different backgrounds. Scholars will prioritize scientific excellence in their own research while creating an inclusive lab climate that serves as a model within their own institutions and beyond. Eligible research areas are in the biological and biomedical sciences and include many scientific disciplines in a wide range of organisms. - Oncology Nursing Foundation Focused Research Grant: Oral Chemotherapy Adherence
Amount: $100,000
Deadline: LOI due May 16, 2024
Eligibility:
This opportunity is intended for established oncology nurse researchers with a demonstrated funding history of at least $50,000 in prior research funding.
The PI (individual primarily responsible for implementing the proposal and reporting to the Oncology Nursing Foundation) must be a registered oncology nurse actively involved in some aspect of cancer patient care, education, or research.
The PI must be PhD prepared (only one PI can appear on the grant).
The PI must have received and completed at least one research study with a funding level of at least $50,000 as the study PI.
About: Supports rigorous scientific oncology nursing research through a major-focused grant. Research projects must address oral chemotherapy adherence. - Oncology Nursing Foundation RE33 General Topic Research Grant
Amount: $100,000
Deadline: LOI due May 16, 2024
Eligibility:
The PI (individual primarily responsible for implementing the proposal and reporting to the Oncology Nursing Foundation) must be a registered oncology nurse actively involved in some aspect of cancer patient care, education, or research.
The PI must be PhD prepared (only one PI can appear on the grant).
The PI must have received and completed at least one research study with a funding level of at least $50,000 as the study PI.
About: Support rigorous scientific oncology nursing research. Research projects may include investigator-initiated research, pilot or feasibility studies, supplements to currently funded projects, or developing a new aspect of a program of research. Funding preference is given to projects that involve nurses in the design and conduct of the research activity and that promote theoretically-based oncology practice. - Oncology Nursing Foundation RE03 General Topic Research Grant
Amount: $50,000
Deadline: LOI due May 16, 2024
Eligibility:
The PI (individual primarily responsible for implementing the proposal and reporting to the Oncology Nursing Foundation) must be a registered oncology nurse actively involved in some aspect of cancer patient care, education, or research.
The PI must be PhD prepared (only one PI can appear on the grant).
At least one member of the research team must have received and completed research study funding of at least $100,000 in a principal investigator capacity, thereby serving as a mentor for the project.
About: Supports rigorous scientific oncology nursing research. Research projects may include investigator-initiated research, pilot or feasibility studies, supplements to currently funded projects, or developing a new aspect of a program of research. Funding preference is given to projects that involve nurses in the design and conduct of the research activity and that promote theoretically-based oncology practice. - Alex’s Lemonade Stand Foundation: 2024 R Accelerated Grant
Amount: Up to $800,000 over 4 years
Deadline: June 6, 2024
Eligibility:
Applicants must be first-time recipients of a pediatric cancer research focused NIH R01 award or equivalent independent award.
Proposals with a sole/primary focus on patients >19 years of age will not be considered.
Applicants need not be United States citizens. Funds must be granted to nonprofit institutions or organizations.
Applicants must have an MD, PhD, or MD/PhD (DO, MBBS or equivalent) and be within ten years of their first faculty appointment at the Assistant Professor level (higher academic ranks allowed) at the time that their application is submitted.
Applicants cannot be lead PIs on active ALSF funded grants concurrent with the R Accelerated Award.
Applicants must be recipients of their first independent award such as R01 and must be within five years of notice of award of this award or its equivalent. A Notice of Award document from the NIH or other funding organization must be submitted with the application. There must be clear documentation of how scientific and budgetary overlap will be avoided.
R01 equivalent NIH awards include the DP1, DP2, DP5, R37, R56, RF1, RL1, U01 and selected R35 activity codes. Applicants with a K99/R00 award are eligible, if the PI is in the first year of the R00 phase of the award at the time of submission.
Funding from other agencies should be peer-reviewed awards of $200,000 (USD) a year for 4 or more years. R01-equivalent grants cannot be mentored-career development awards.
All interested applicants with a non-NIH grant thought to be R01-equivalent must contact Margaret Poore at M.Poore@AlexsLemonade.org at least 4 weeks before application due date to determine if the applicant is eligible to apply under the R01- equivalent category.
About: The purpose of the R Accelerated Award Grant is to advance ALSF’s mission to find cures and better treatments for childhood cancers by providing support to scientists focused on pediatric oncology research. Applicants must have an original project that is not currently being funded that has a clear focus on accelerating the discovery of more effective, less toxic therapies for childhood cancers. Research projects should address a testable hypothesis based on strong scientific rationale. Demonstration of continued commitment to pediatric cancer investigation as well as institutional support are critical components of a successful application. - Craig H. Neilson Foundation: SCIRTS Senior Research Grants
Amount: Up to $800,000 over 3 years
Deadline: LOI due June 7, 2024
Eligibility:
This category is for individuals who are established, independent investigators in a position equivalent to Associate Professor or above, employed at the grantee institution at the time of the FGA submission.
A PI may submit only one application in each cycle in this portfolio
The Neilsen Foundation does not recognize Co-Principal Investigators—if two or more investigators are working together on a research project, name only one as the Applicant; the other(s) should be listed as collaborator(s). Collaborators and/or consultants do not need to be affiliated with the same institution as the PI; a subcontract may be used to support a domestic or international collaborator or consultant.
Multiple PIs from an institution may submit concurrent, independent applications in a given grant cycle. In such cases, each project must be distinct, with non-overlapping Aims.
The Neilsen Foundation discourages Postdoctoral Fellows and their mentor(s) from submitting concurrent applications with overlapping Aims to multiple funding categories within this portfolio.
About: This funding is intended to encourage pursuit of new avenues, enable paradigm shifts, or support decisive translational steps in developing SCI treatments. Applicants should propose transformative projects that explore new areas of SCI research or fill important gaps in the field. - Craig H. Neilson Foundation: SCIRTS Pilot Research Grants
Amount: Up to $400,000 over 2 years
Deadline: LOI due June 7, 2024
Eligibility:
Applicants must have a doctoral degree or other equivalent terminal professional degree, be beyond the postdoctoral level (i.e., Instructor, Assistant Professor, or equivalent research position) at the time of the FGA submission, and demonstrate appropriate experience to serve as an independent PI.
A PI may submit only one application in each cycle in this portfolio (see below: PART 3, B. Concurrent Grants Across Neilsen Foundation Portfolios).
The Neilsen Foundation does not recognize Co-Principal Investigators—if two or more investigators are working together on a research project, name only one as the Applicant; the other(s) should be listed as collaborator(s). Collaborators and/or consultants do not need to be affiliated with the same institution as the PI; a subcontract may be used to support a domestic or international collaborator or consultant.
Multiple PIs from an institution may submit concurrent, independent applications in a given grant cycle. In such cases, each project must be distinct, with non-overlapping Aims.
The Neilsen Foundation discourages Postdoctoral Fellows and their mentor(s) from submitting concurrent applications with overlapping Aims to multiple funding categories within this portfolio.
About: This funding is intended to support pilot studies that lay essential groundwork, allow either junior or established PIs to test the feasibility of novel methods and procedures and/or collect new data that can lead to or enhance larger-scale studies - Craig H. Neilson Foundation: SCIRTS Postdoctoral Fellowship
Amount: Up to $200,000 over 2 years
Deadline: LOI due June 7, 2024
Eligibility:
Fellows must have attained their doctoral degree or an equivalent terminal professional degree by the LOI submission deadline and have held that degree no longer than five years before the FGA submission deadline. For Fellows with a MD, the five-year eligibility period begins after completion of the residency program.
A PI may submit only one application in each cycle in this portfolio (see below: PART 3, B. Concurrent Grants Across Neilsen Foundation Portfolios).
The Neilsen Foundation does not recognize Co-Principal Investigators—if two or more investigators are working together on a research project, name only one as the Applicant; the other(s) should be listed as collaborator(s). Collaborators and/or consultants do not need to be affiliated with the same institution as the PI; a subcontract may be used to support a domestic or international collaborator or consultant.
Multiple PIs from an institution may submit concurrent, independent applications in a given grant cycle. In such cases, each project must be distinct, with non-overlapping Aims.
The Neilsen Foundation discourages Postdoctoral Fellows and their mentor(s) from submitting concurrent applications with overlapping Aims to multiple funding categories within this portfolio.
About: The SCIRTS Portfolio advances novel approaches to improving function and developing curative therapies after spinal cord injury (SCI). This research is designed to improve understanding and advance the treatment of acute and chronic SCI and includes mechanistic, preclinical, translational and/or clinical studies.
This funding is designed to encourage specialization in the field of SCI; Fellowships are intended to provide mentored training in SCI research to early-career investigators. The Fellowship Applicant (Fellow) should be mentored (or co-mentored) by an investigator experienced in SCI research. - CURE Epilepsy: Rare Epilepsy Partnership Award
Amount: $100,000 over 1 year
Deadline: June 11, 2024
Eligibility: This award is available to both established and early-career investigators. Early career investigators must have a mentor committed to advising the applicant. A clearly articulated mentorship statement from the mentor must be submitted along with the application. See RFP for details.
About: Supports the development of necessary research tools, techniques, model systems, and data collection platforms to stimulate and accelerate research on rare epilepsies. Each award will be co-funded by CURE Epilepsy and one or more of the rare epilepsy advocacy groups (partners) identified in the Request For Proposals. Applications must focus on one or more of the specific rare epilepsies that are represented by each group as well as address CURE Epilepsy’s mission to cure epilepsy. - Alex’s Lemonade Stand: 2024 ‘A’ Award Grant
Amount: Up to $800,000 over 4 years
Deadline: June 13, 2024
Eligibility:
Proposals with a sole/primary focus on patients >19 years of age will not be considered.
Applicants need not be United States citizens.
Applicants must have an MD, PhD or MD/PhD (DO, MBBS or equivalent) and be within ten years of their terminal degree and five years of their first faculty appointment as an Assistant Professor at the time that their application is submitted. More senior Assistant Professors, as well as Associate and Full Professors, are ineligible. If still at the Instructor level, the applicant must have a firm commitment from the Department Chair/Division Chief at the time of grant submission for an Assistant Professor position within one year of receiving the award.
A minimum of 75% of the applicant’s time during the ‘A’ Award period must be allocated as non-clinical protected time for all research activities. This percentage of time includes both ‘A’ Award activities and the applicant’s other research responsibilities.
Mentor(s) must be identified and must be in the applicant’s home institution. A co-mentor whose research expertise is aligned with the application could be added from an outside institution.
Applicants cannot be the Principal Investigator (PI) of a K99/R00 or other independent, nationally competitive award (e.g., R01 or equivalent, P or U award) that has been funded or recommended for funding (i.e., will be funded) any time before the ‘A’ Award grant start date. R01 equivalent grants include the DP1, DP2, DP5, R01, R37, R56, RF1, RL1, U01 and selected R35 activity codes. Applicants cannot have 2 R21s or 2 R03s at any time before the award. Applicants, when unsure, are encouraged to contact ALSF at least 4 weeks before the application due date to determine eligibility.
Applicants may have mentored-career development grants (such as K01, K08, K23, K25) or mentored-research grants (such as ACS-Clinician Scientist Development Grant; DoD Physician Research Award) from other funding sources during the ‘A’ Award period, but there must be clear documentation of how scientific and budgetary overlap will be avoided.
Applicants currently holding an ALSF Young Investigator (YI) Grant may apply. If the ‘A’ Award is given, it would supersede the YI grant if there is an overlap in the funding periods
About: Supports early career scientists who want to establish a career in pediatric oncology research. The ideal applicant has an original project that is not currently being funded. Demonstration of a future commitment to pediatric cancer investigation as well as institutional support for the career development of the investigator are critical components of a successful application. A mentor is required, and a career development plan must be included. - American Association of Neurological Surgeons: William P. Van Wagenen Fellowship
Deadline: November 1, 2024
Amount: $120,000 over 1 yr
Eligibility: The fellowship is open to all senior neurosurgical residents (PGY6 & PGY7) in approved neurosurgery residency programs whose intent is to pursue an academic career in neurological surgery. It is offered strictly as a post-residency fellowship. - Colorectal Cancer Alliance: Pilot Award
Amount: Up to $200,000 over 2 years
Deadline: Rolling; responses should be received 1 month following submission
Eligibility:
Applicants must have an academic or industrial research appointment and will be considered on a case-by-case basis.
About: Pilot Awards support investigators who propose potentially transformative ideas that do not have extensive preliminary data but articulate a clear hypothesis and translational goals. Resources for such “high-risk, high-reward” projects are important to establish proof-of-concept, which may then leverage additional funding through more traditional avenues. - Colorectal Cancer Alliance: Early-Career Investigator Award
Amount: $200,000 over 2 years
Deadline: Rolling; responses should be received 1 month following submission
Eligibility:
Applicants must be within the first five years of their first independent, full-time academic faculty appointment.
About: Early-Career Investigator Awards aim to attract early career faculty with original ideas into the field of colorectal cancer research, thereby recruiting and supporting the next generation of CRC research leaders. Awardees will be provided funding to accomplish innovative and original, preclinical, translational, and/or early clinical research projects. - Colorectal Cancer Alliance: Senior Investigator Award
Amount: Up to $2 million over 2 years
Deadline: Rolling; responses should be received 1 month following submission
Eligibility:
Principal Investigator must be a senior researcher, past the initial five years of their first academic faculty appointment.
Key collaborators are not required to qualify as a senior researcher
About: Senior Investigator Awards will fund potentially transformative ideas that will accelerate the translation of new therapies and technologies. Proposals may include investigator-initiated clinical trials and do not require IRB approval at the proposal stage. Collaborations are highly encouraged. - Colorectal Cancer Alliance: Team Science Award
Amount: Up to $6 million over 3 years
Deadline: Rolling; responses should be received 1 month following submission
Eligibility:
Principal Investigator of Team Award proposal must be a senior investigator with more than five years of active research in colorectal cancer.
Research teams may be from a single institution or multiple institutions.
Research teams may include both academic and industry (biotech/pharma) researchers
About: The Team Science Award will support team science, including public-private partnerships, that will drive CRC research to curative science. Research proposals that accelerate new innovations from bench to bedside and address current unmet clinical needs will be prioritized. - SFARI Supplement to Enhance Equity and Diversity
Amount: $300,000 over 3 years
Deadline: Rolling
Eligibility:
Principal Investigators from institutions in the United States with a current SFARI grant that has at least 18 months remaining on the project are eligible to apply for this supplement.
Must be used to add a new lab member from American underrepresented minority groups at the postdoctoral level. The postdoctoral research associate must also be a United States citizen.
About: Supplements existing SFARI grants prioritizing the advancement of autism science for the recruitment of new lab members from American underrepresented minority groups at the postdoctoral level. SFARI Principal Investigators (PIs) are encouraged to recruit candi¬¬¬¬¬¬¬¬dates for this supplement not only at their home institution, but also at historically Black colleges and universities and other institutions with high minority enrollment. - Cystic Fibrosis Foundation: Therapeutics Development Award
Deadline: rolling
In an effort to stimulate development of new pharmaceutical products for CF patients, CFF developed the “Therapeutics Development Award” Program. The purpose of this program is to provide funds to companies that will develop commercial products to benefit individuals with CF. Structured as a matching award program, funds will be awarded only if they are matched by the recipient. - Foundation Fighting Blindness: Ted and Elaine Welp Enhanced Career Development Program Award (Enhanced CDA)
Rolling Submission
Amount/Duration: $170,000 per year for up to three years.
Eligibility: Applicants must possess an M.D. or M.D./Ph.D. degree, hold a full-time tenure-track or equivalent appointment at the sponsoring institution with a commitment of no less than five (5) years, commit at least 80% of their work hours to the program, and have successfully completed an ophthalmology residency or equivalent training.
About: The Enhanced CDA ensures that an adequate pool of highly trained physicians/scientists are available to address current and future needs and opportunities for clinical research and therapy related to inherited orphan retinal degenerative diseases. This award supports and provides protected career development time to individuals with M.D. and M.D./Ph.D. degrees to further their independent research in retinal degenerative diseases. - Robert Wood Johnson: research to advance racial equity
Deadline: rolling
Amount: no max listed
About: This funding is focused on studies about upstream causes of health inequities, such as the systems, structures, laws, policies, norms, and practices that determine the distribution of resources and opportunities, which in turn influence individuals’ options and behaviors. Research should center on the needs and experiences of communities exhibiting the greatest health burdens and be motivated by real-world priorities. It should be able to inform a specific course of action and/or establish beneficial practices, not stop at characterizing or documenting the extent of a problem. - Simons Foundation: Autism Research Initiative SFARI Supplement to Enhance Equity and Diversity (SEED)
Rolling Submissions
Amount/Duration: Up to $100,000 per year for up to 3 years.
About: The SFARI Supplement to Enhance Equity and Diversity (SEED) is a new program that provides supplements to existing grants for the recruitment of new lab members from American underrepresented minority groups at the postdoctoral level. The goal of this award is to increase diversity and fight inequity. SFARI Principal Investigators (PIs) are encouraged to recruit candidates for this supplement not only at their home institution but also at historically Black colleges and universities and other institutions with high minority enrollment. - How to Apply – Warner Fund
Deadline: Rolling
Amount: $75,000
About: seeks to provide support for programs designed improve the lives of children in foster care and children with disabilities. The Warner Fund gives preference to innovative projects with measurable results and the likelihood of replication. Funding will only be considered after a comprehensive sustainability plan with a timeline of events has been developed and submitted for review. - PNC Foundation: Grow up great
Deadline: rolling deadline
Amount: $50,000-100,000
About: Educational programs for children and youth, particularly early education initiatives supported through PNC Grow Up Great that serve low-and moderate-income children (birth through age five), their teachers and families may be considered for funding.